BioWorld MedTech

Feb. 11, 2015

Agendia receives new FDA clearance for MammaPrint

Molecular diagnostics company Agendia (Irvine, California) reported that it has received FDA 510(k) clearance for its MammaPrint breast cancer recurrence test in FFPE (formalin-fixed paraffin embedded) tissue. Read More

Latin America: Venezuela turns to China to alleviate medical device shortage

MDD Interview: French crowds say 'oui' to funding as EyeBrain raises $1.5 million

Inside the Beltway: AdvaMed highlights coverage of FDA-approved medical device trials

World in Review: Data from British Journal of Surgery supports Medtronic's ClosureFast

Seeking tax reform, U.S. Senate committee examines 1986 overhaul

Agreements/contracts: CWRU, Cleveland Clinic win DoD bid for prosthetic limb research

Financings: AxoGen closes public offering of stock for around $13 million

People in Places

Patent Watch: HCi Viocare files application for wearable devices, motion capture

Product Briefs

MDD's Oncology Extra

Today's news in brief

BioWorld

BioWorld briefs for April 4, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 4, 2025.

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

3D rendering of glucagon-like peptide 1 (GLP-1)

ADPD 2025: Unlocking GLP-1's potential in neurodegeneration

BioWorld

At the recently launched Alzheimer’s & Parkinson’s Diseases Conference held in Vienna, Lotte Bjerre Knudsen from Novo Nordisk A/S, who has extensive experience in...

Immune checkpoint inhibitors illustration of PD-1, CTLA-4 and PD-L1.

Checkpoint inhibitor journey traces Chinese firms’ path to global revenue

BioWorld

Chinese pharmaceutical companies are making significant inroads into the global oncology market, particularly with the development and approval of immune...